If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Director/PDMR Shareholding

23 Apr 2019 15:35

RNS Number : 8431W
Premier Veterinary Group PLC
23 April 2019
Β 

Β 

Β 

PREMIER VETERINARY GROUP PLC

Β 

NOTIFICATION OF TRANSACTIONS OF PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMR)

Β 

London, UK, 23 April 2019 (LSE: PVG):Β Premier Veterinary Group plc ("the Company") announces that it has on 26 February 2019:

Β 

Issued Warrants to subscribe to 537,143 ordinary shares of 10 pence each ("Ordinary Shares") in the Company to Bybrook Finance Solutions Limited ("BFSL" a company of which Rajan Uppal, a director of PVG, is the sole director and Shareholder);

Pending exercise of the warrants, there is no change to Mr Uppal's beneficial interest as a result of this transaction, this being 5,421,138 Ordinary Shares in the Company, representing 35.324% of the total voting rights of the Company.

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

Β 

1

Details of the person discharging managerial responsibilities/person closely associated

Β 

a)

Name

Β 

Β 

Rajan UPPAL

2

Reason for the notification

Β 

a)

Position/status

Β 

Corporate Development Director

b)

Initial notification/ Amendment

Β 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Name

Premier Veterinary Group plc

Β 

b)

LEI

Β 2138009B5L8VQUZ9A719

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

a)

Description of the financial instrument, type of instrument

Β 

Identification code

Β 

Warrants to subscribe for new ordinary shares of Β£0.10 each

Β 

Β 

Β 

ISIN: GB00BSZLMS59

b)

Nature of the transaction

Issue of warrants

Β 

c)

Price(s) and volume(s)

Β 

Price(s)

Volume(s)

Β 

Β£0.10

537,143 shares

Β 

Β 

d)

Aggregated information

Β 

- Aggregated volume

- Price

Β 

Β 

Aggregate Price

Aggregate Volume

Aggregate Total

Β 

N/A

N/A

N/A

e)

Date of the transaction

2019-04-23

Β 

f)

Place of the transaction

Outside of a trading venue

Β 

Β 

For further information, please contact:

Premier Veterinary Group plc

Dominic Tonner, Chief Executive Officer

Andy Paull, Chief Financial Officer

Β 

Tel: +44 (0)117 970 4130

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
DSHLLFFSSAIVFIA
Date   Source Headline
6th Jun 20122:41 pmRNSBlocklisting Interim Review
18th May 201212:02 pmRNSHolding(s) in Company
18th May 201212:01 pmRNSDirector Dealings
18th May 201211:57 amRNSResult of AGM
17th May 20127:00 amRNSInterim Management Statement
16th May 20127:00 amRNSCompletion of Phase 1 Study
2nd May 20127:00 amRNSGrant and Patent Update
25th Apr 20127:00 amRNSRegulatory Approval of Manufacturing Suite
17th Apr 20122:36 pmRNSDirector/PDMR Shareholding
10th Apr 20127:00 amRNSNew Board Appointment
2nd Apr 20123:25 pmRNSAnnual Information Update
26th Mar 20127:00 amRNSChange of Broker Name
15th Mar 20124:09 pmRNSDirector/PDMR Shareholding
13th Mar 20124:16 pmRNSBoard Changes
12th Mar 20127:00 amRNSFinal Results
23rd Feb 20124:29 pmRNSHolding(s) in Company
9th Feb 201211:10 amRNSNotice of Results
8th Feb 20127:00 amRNSUS patent for Neuropilin-1 receptor
4th Jan 20127:00 amRNSManufacturing Update
7th Dec 201111:48 amRNSDirector/PDMR Shareholding
5th Dec 20112:35 pmRNSBlocklisting Interim Review
9th Nov 20117:00 amRNSInterim Management Statement
3rd Nov 20117:00 amRNSManufacturing agreement
16th Sep 20114:41 pmRNSSecond Price Monitoring Extn
16th Sep 20114:35 pmRNSPrice Monitoring Extension
12th Sep 20117:00 amRNSRe Agreement
24th Aug 20115:29 pmRNSHalf Yearly Report on National Storage Mechanism
24th Aug 20117:00 amRNSHalf Yearly Report - Part 2
24th Aug 20117:00 amRNSHalf Yearly Report - Part 1
1st Aug 20114:31 pmRNSHolding(s) in Company
29th Jul 20114:40 pmRNSSecond Price Monitoring Extn
29th Jul 20114:35 pmRNSPrice Monitoring Extension
25th Jul 20114:40 pmRNSSecond Price Monitoring Extn
25th Jul 20114:35 pmRNSPrice Monitoring Extension
18th Jul 20113:10 pmRNSHolding(s) in Company
14th Jul 20117:00 amRNSWins ?5.3 million EU Framework Programme 7 Grant
6th Jul 20117:00 amRNSArk receives Finnish Grants
4th Jul 20117:00 amRNSGrant of US patents and milestone payments
13th Jun 20114:40 pmRNSSecond Price Monitoring Extn
13th Jun 20114:35 pmRNSPrice Monitoring Extension
3rd Jun 201111:57 amRNSBlocklisting Interim Review
17th May 20117:00 amRNSInterim Management Statement
9th May 20113:28 pmRNSAGM Results
31st Mar 20111:43 pmRNSAnnual Information Update
30th Mar 20111:08 pmRNSDirector/PDMR Shareholding
24th Mar 20113:40 pmRNSAnnual Financial Report
9th Mar 20117:00 amRNSFinal Results
3rd Mar 20117:00 amRNSAppointment of CFO
2nd Mar 20117:00 amRNSDisposal
28th Feb 201111:49 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.